Abstract A141: Precision population cancer medicine for pancreatic ductal adenocarcinoma: A framework integrating genomics, artificial intelligence, theranostics, and population health
Pancreatic ductal adenocarcinoma (PDAC) remains among the deadliest malignancies, with a 5-year survival rate of approximately 13%. Advances in genomics, artificial intelligence (AI), liquid biopsy, and theranostics have expanded opportunities for precision oncology; however, implementation remains uneven across...